Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Invivyd ( (IVVD) ) has shared an update.
On November 17, 2025, Invivyd, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. for a public offering of 44,000,000 shares of common stock and pre-funded warrants for 6,000,000 shares, raising approximately $117.2 million. The proceeds will support the commercial preparedness for VYD2311, ongoing research and development, and other corporate purposes, potentially impacting the company’s market position and stakeholders.
The most recent analyst rating on (IVVD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.
Spark’s Take on IVVD Stock
According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.
Invivyd’s overall stock score reflects significant financial and technical weaknesses, marked by ongoing losses and bearish trends. While recent corporate developments offer a glimpse of potential strategic improvement, these are overshadowed by the current financial instability and weak market sentiment.
To see Spark’s full report on IVVD stock, click here.
More about Invivyd
Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2. The company utilizes a proprietary integrated technology platform to develop and adapt antibodies, and it received emergency use authorization from the U.S. FDA in March 2024 for a monoclonal antibody in its pipeline.
Average Trading Volume: 10,536,959
Technical Sentiment Signal: Buy
Current Market Cap: $662.1M
Learn more about IVVD stock on TipRanks’ Stock Analysis page.